A multimodal, digital community-based intervention was feasible and decreased illness-related distress in treating patients ...

Pneuma Respiratory, a med-tech and pharmaceutical company dedicated to advancing inhaled respiratory therapeutics, is introducing new transformational approaches to respiratory health to improve the ...

Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported ...

St. Vincent’s Riverside is now offering a breakthrough treatment for patients diagnosed with chronic pulmonary obstructive ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

At that point, COPD may be significantly advanced, increasing the likelihood a person will need hospitalization or more intensive treatments. Davis explained: “Stopping smoking is the simplest ...

Among patients with COPD, those receiving 6-week nicotinamide riboside, “a B3-like vitamin,” had significantly decreased lung ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit ... and Harvard Medical School, first author of this study.

Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...

During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...

3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD ...